Diffractaic acid exhibits thioredoxin reductase 1 inhibition in lung cancer A549 cells

Area of Science:

• Pharmacology
• Oncology
• Natural Products Chemistry

Background:

• Lung cancer remains a leading global cause of cancer mortality, necessitating novel chemotherapeutic agents.
• Thioredoxin reductase 1 (TrxR1) is overexpressed in lung tumors, making it a significant therapeutic target.
• Lichen secondary metabolites are a source of potential anticancer compounds.

Purpose of the Study:

• To evaluate the anticancer efficacy of diffractaic acid, a lichen metabolite, in A549 lung cancer cells.
• To compare diffractaic acid's cytotoxicity with carboplatin, a standard chemotherapeutic drug.
• To investigate the mechanism of action, specifically targeting thioredoxin reductase 1 (TrxR1).

Main Methods:

• Cytotoxicity assays (IC50 determination) and cell viability assessment.
• Quantitative PCR (qPCR) and flow cytometry to analyze apoptotic pathways.
• Cell migration assays and enzymatic activity assays for TrxR1.

Main Results:

• Diffractaic acid exhibited stronger cytotoxicity than carboplatin against A549 cells (IC50 = 46.37 μg/mL at 48h).
• It induced apoptosis via the intrinsic pathway by upregulating the BAX/BCL2 ratio and P53 gene expression.
• Diffractaic acid significantly inhibited TrxR1 enzymatic activity without altering gene or protein expression levels, and suppressed A549 cell migration.

Conclusions:

• Diffractaic acid demonstrates significant anticancer potential against lung cancer cells.
• Its mechanism involves the inhibition of TrxR1 enzymatic activity, induction of apoptosis, and suppression of cell migration.
• Diffractaic acid warrants further investigation as a potential chemotherapeutic agent for lung cancer treatment.